SALT LAKE CITY and TORONTO, January 23, 2015 (PRNewswire/-) EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules receives an NPN (Natural Product Number) from the Natural and Non-Prescription Health Products Directorate of Health Canada for its natural product Glucora.
The NPN product license number for Glucora is 80057426. Glucora is a natural based formula in self-emulsifying delivery system that provides support for healthy glucose metabolism.
Glucora is an addition to a line of natural products, developed at EastGate Biotech Corp. The products are currently available online at www.nano-essentials.com. As previously announced, the products will be also available under private label by a distributor in the United States.
EastGate Biotech’s R&D strategy and product analysis included the identification of biologically active compounds having limited absorption due to low solubility. Low absorption of drugs and poor bioavailability can lead to increased dosages taken by patients with the same treatment result. Increased bioavailability could encourage patient compliance, lower costs of treatment , reduce side effects and improve quality of life.
EastGate Biotech’s technology platform provides an effective delivery system with increased bioavailability of incorporated compounds. The Company’s approach increases solubility of hydrophobic compounds in a proprietary self-emulsifying vehicle using a safe combination of known and approved excipients. To date, the Company’s sub-micron self-emulsifying delivery platform has been used for improvement of dietary supplements as well as pharmaceutical products. Intraoral Lorazepam Spray for seizure treatment and in intraoral insulin tablet for diabetes are in advanced stages of development.
“We are pleased with the addition of NPN license for our product Glucora” says Anna Gluskin, EastGate’s CEO. “Both the nutraceutical and pharmaceutical industries are consistently looking out for innovative products in the area of glucose metabolism regulation that improve patient compliance, since the consumer demand in diabetes management is growing”, continues Ms. Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Rose Perri 1-647-692-0652